BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33137377)

  • 1. Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets.
    Nameki R; Chang H; Reddy J; Corona RI; Lawrenson K
    Pharmacol Ther; 2021 Apr; 220():107722. PubMed ID: 33137377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
    Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.
    Mehrotra M; Phadte P; Shenoy P; Chakraborty S; Gupta S; Ray P
    Adv Exp Med Biol; 2024; 1452():65-96. PubMed ID: 38805125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study.
    Calura E; Ciciani M; Sambugaro A; Paracchini L; Benvenuto G; Milite S; Martini P; Beltrame L; Zane F; Fruscio R; Marchette MD; Borella F; Tognon G; Ravaggi A; Katsaros D; Bignotti E; Odicino F; D'Incalci M; Marchini S; Romualdi C
    Cells; 2019 Dec; 8(12):. PubMed ID: 31805750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
    Fan Q; Cai Q; Xu Y
    Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.
    Yoffou PH; Edjekouane L; Meunier L; Tremblay A; Provencher DM; Mes-Masson AM; Carmona E
    PLoS One; 2011; 6(6):e20705. PubMed ID: 21695196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
    Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
    Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
    Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
    Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.
    Guan L; Li Z; Xie F; Pang Y; Zhang C; Tang H; Zhang H; Chen C; Zhan Y; Zhao T; Jiang H; Jia X; Wang Y; Lu Y
    J Exp Clin Cancer Res; 2020 Mar; 39(1):53. PubMed ID: 32293499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.
    Sun Y; Hu L; Zheng H; Bagnoli M; Guo Y; Rupaimoole R; Rodriguez-Aguayo C; Lopez-Berestein G; Ji P; Chen K; Sood AK; Mezzanzanica D; Liu J; Sun B; Zhang W
    J Pathol; 2015 Jan; 235(1):25-36. PubMed ID: 25230372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.
    Calura E; Fruscio R; Paracchini L; Bignotti E; Ravaggi A; Martini P; Sales G; Beltrame L; Clivio L; Ceppi L; Di Marino M; Fuso Nerini I; Zanotti L; Cavalieri D; Cattoretti G; Perego P; Milani R; Katsaros D; Tognon G; Sartori E; Pecorelli S; Mangioni C; D'Incalci M; Romualdi C; Marchini S
    Clin Cancer Res; 2013 Aug; 19(15):4114-23. PubMed ID: 23766361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.
    Li H; Wu N; Liu ZY; Chen YC; Cheng Q; Wang J
    Sci Rep; 2021 Mar; 11(1):7207. PubMed ID: 33785763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer.
    Chen YF; Wang SY; Yang YH; Zheng J; Liu T; Wang L
    Int J Mol Med; 2017 Jun; 39(6):1564-1570. PubMed ID: 28487934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.